News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
359,654 Results
Type
Article (18499)
Company Profile (65)
Press Release (341090)
Section
Business (117778)
Career Advice (1112)
Deals (21784)
Drug Delivery (55)
Drug Development (41578)
Employer Resources (73)
FDA (8702)
Job Trends (8316)
News (191014)
Policy (16344)
Tag
Academia (1705)
Africa (403)
Alliances (27021)
Alzheimer's disease (709)
Approvals (8670)
Arizona (69)
Artificial intelligence (51)
Asia (21153)
Australia (3833)
Bankruptcy (193)
Best Places to Work (6985)
Biosimilars (47)
Biotechnology (54)
Breast cancer (41)
C2C Services and Suppliers (36989)
California (1295)
Canada (562)
Cancer (373)
Career advice (914)
Cell therapy (102)
China (104)
Clinical research (32424)
Collaboration (109)
Colorado (60)
Compensation (94)
Connecticut (46)
COVID-19 (1441)
Cystic fibrosis (48)
Data (306)
Diabetes (46)
Diagnostics (3355)
Drug pricing (41)
Earnings (36240)
Employer resources (67)
Europe (46934)
Events (46870)
Executive appointments (140)
FDA (8893)
Florida (184)
Funding (115)
Gene therapy (71)
Georgia (42)
GLP-1 (255)
Government (2592)
Healthcare (11432)
Hotbed/Location (250054)
Illinois (166)
Indiana (106)
Infectious disease (1463)
Inflammatory bowel disease (77)
Interviews (206)
IPO (11300)
Job creations (1438)
Job search strategy (788)
Kansas (48)
Layoffs (176)
Legal (3304)
Lung cancer (89)
Manufacturing (81)
Maryland (306)
Massachusetts (958)
Medical device (7922)
Medtech (7924)
Mergers & acquisitions (10507)
Metabolic disorders (110)
Michigan (99)
Minnesota (107)
Neuroscience (802)
New Jersey (409)
New York (391)
NextGen Class of 2024 (4063)
Non-profit (2982)
North Carolina (423)
Northern California (588)
Obesity (48)
Ohio (78)
Opinion (103)
Pennsylvania (371)
People (45940)
Phase I (10384)
Phase II (14398)
Phase III (10843)
Pipeline (106)
Policy (47)
Postmarket research (1081)
Preclinical (4155)
Press Release (67)
Radiopharmaceuticals (159)
Rare diseases (83)
Real estate (2922)
Regulatory (11094)
Research institute (1577)
Resumes & cover letters (178)
South America (574)
Southern California (548)
Startups (2374)
Texas (186)
United States (5737)
Vaccines (270)
Washington State (161)
Date
Last 7 days (385)
Last 30 days (1534)
Last 365 days (22382)
2024 (16773)
2023 (25102)
2022 (31442)
2021 (33577)
2020 (32637)
2019 (27980)
2018 (21199)
2017 (19380)
2016 (17485)
2015 (20760)
2014 (14881)
2013 (11993)
2012 (12386)
2011 (12715)
2010 (10915)
359,654 Results for "direct biologics llc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Diagnostics Direct, LLC Announces Formation of a Medical Advisory Board
Diagnostics Direct LLC, a leading provider of diagnostic testing solutions, is proud to announce the formation of its distinguished Medical Advisory Board.
March 13, 2024
·
3 min read
Press Releases
NLS Pharmaceutics Announces Registered Direct Offering
NLS Pharmaceutics Ltd. announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,277,750 of its common shares at a purchase price of $0.24 per share in a registered direct offering.
June 28, 2024
·
6 min read
Press Releases
Humacyte Announces Pricing of $30.0 Million Registered Direct Offering
October 4, 2024
·
6 min read
Pharm Country
BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering
BrainStorm Cell Therapeutics Inc announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 11,111,111 shares of the Company’s common stock at a purchase price of $0.36 per share in a registered direct offering.
June 27, 2024
·
5 min read
Genetown
Samsung Biologics selects Rapid Micro Biosystems’ Growth Direct® platform to automate critical microbiology quality control testing
Rapid Micro Biosystems, Inc. announced that Samsung Biologics has selected the Growth Direct® platform to automate its microbial quality control processes to deliver increased efficiency, more robust data integrity and scalable quality control operations.
January 4, 2024
·
5 min read
Press Releases
AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering
September 30, 2024
·
4 min read
Deals
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
Enlivex Therapeutics Ltd. today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale in a registered direct offering of an aggregate of 3,571,429 ordinary shares.
May 28, 2024
·
6 min read
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
Enlivex Therapeutics Ltd. announced the closing of its previously announced registered direct offering to a single healthcare-focused institutional investor of an aggregate of 3,571,429 ordinary shares and clinical milestone-linked warrants.
May 29, 2024
·
5 min read
Deals
AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 5,640,958 shares of common stock in a registered direct offering at a purchase price of $0.363 per share.
May 31, 2024
·
4 min read
Bio NC
ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
ProKidney Corp. announced that it has commenced an underwritten public offering and a concurrent registered direct offering of up to an aggregate of $125 million of its Class A ordinary shares, before deducting underwriting discounts and commissions and other offering expenses.
June 10, 2024
·
5 min read
1 of 35,966
Next
